Turenne and BNP Paribas Développement completed the acquisition of a minority stake in H.A.C. Pharma.

Private equity firms Turenne and BNP Paribas Développement, completed the acquisition of a minority stake in H.A.C. Pharma, a pharmaceutical company. Financial terms were not disclosed. “BNP has been at our side since the creation of HACPharma and we share with the Turenne team a common vision of our business dedicated to serving healthcare professionals and patients. The arrival of BNP and Turenne is for all of our employees the opportunity to develop our organization while remaining faithful to our values ​​and capitalizing on the talent of our teams, it is a new stage in the history of 'HACPharma with a strong desire to acquire new molecules and develop our portfolio by creating synergies with our current specialties," Philippe Bissay, H.A.C. Pharma Chairman and CEO.